Jefferies Upgrades ABIVAX Rating to Buy with $158 Target

Jefferies has upgraded ABIVAX Socie9te9 Anonyme (NasdaqGM:ABVX) to a Buy rating, setting a new price target of $158. The upgrade was announced by analyst Faisal Khurshid on June 30, 2026, reflecting a positive outlook on the biotechnology company's prospects.

What Changed in Jefferies' ABIVAX Position

Jefferies raised its rating on ABIVAX to Buy, a shift from its previous stance. The firm now sees the stock reaching a price of $158, signaling confidence in the company's future performance.

Other Institutional Activity in ABIVAX

TCG Crossover Management, LLC reduced its holdings in ABIVAX by 630,511 shares, ending with 6,481,085 shares valued at approximately $721.7 million, marking an 8.9% decrease. UBS Group AG, on the other hand, increased its stake by 123,500 shares, bringing its total to 4,547,406 shares worth about $506.4 million, a 2.8% rise. Darwin Global Management, Ltd. added 290,156 shares, resulting in 3,468,657 shares valued at $352.1 million, reflecting a 9.1% increase. Morgan Stanley trimmed its holdings by 1,447,036 shares, leaving it with 1,704,958 shares worth about $189.8 million, a 45.9% decrease.

ABIVAX Société Anonyme Stock Up 18.6%

Shares of ABIVAX traded near $132.83 on Wednesday. The company has a market capitalization of approximately $7.78 billion. Despite having a negative forward P/E ratio of -29.59, indicative of current unprofitability, the stock has shown a 52-week range from $7.41 to $148.83. Its 50-day moving average is $111.58, while the 200-day moving average stands at $111.21. ABIVAX maintains a strong liquidity position with a current ratio of 8.25 and a quick ratio of 8.07, though it carries a debt-to-equity ratio of 7.96.

Recent Earnings

ABIVAX reported revenue of $4.92 million, with a revenue growth rate of 35.2%. However, the company posted a net margin of 0% and a return on equity of -157.07%, indicating ongoing financial challenges. The next earnings report is expected on September 21, 2026.

Insider Buying and Selling at ABIVAX Société Anonyme

Recent insider activity at ABIVAX includes sales by Sofinnova Crossover. On January 8, 2026, Sofinnova sold 1,000,000 shares at an average price of $133.70. Earlier, on October 28, 2025, Sofinnova Crossover SLP sold 1,200,000 shares at $92.75.

Analysts Set New Price Targets

On June 30, 2026, Jefferies upgraded ABIVAX to a Buy with a target price of $158. On the same day, Leerink Partners and BTIG maintained their Buy ratings, setting targets at $148 and $175, respectively. The consensus among 11 analysts is a Buy, with a mean target price of $150.73.

About ABIVAX Socie9te9 Anonyme

ABIVAX Socie9te9 Anonyme is a biotechnology company based in Paris, France. It focuses on developing treatments that leverage the body's natural mechanisms to manage chronic inflammatory diseases. The company's leading drug candidate, Obefazimod, is in advanced clinical trials for ulcerative colitis and Crohn's disease. Founded in 2013, ABIVAX is led by CEO Marc de Garidel and employs around 80 people.

Bottom Line

Jefferies' upgrade of ABIVAX to a Buy with a $158 price target highlights the firm's bullish outlook on the company's potential. While the stock has shown significant volatility, with a wide 52-week range, analysts remain optimistic. Investors will continue to watch ABIVAX's progress in its clinical trials and financial performance closely.